1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Envoy Medical, Inc.

Envoy Medical, Inc.

COCHW
Envoy Medical, Inc.US flagNASDAQ Capital Market
0.05
USD
+0.00
- -
1.04MMarket Cap
Envoy Medical, Inc.
COCHW
(NASDAQ Capital Market)

Recent

price

0.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-2,216.45
-3,673.42
-5,809.81
-8,558.22
-9,240.66
-9,881.2
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
-9
-16
-30
-21
-24
-23
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-2,798.39
-6,718.57
-9,468.99
-9,242.22
-9,857.26
-9,875.64
Profit Margin (%)
1
-1
- -
1
-5
15
Working Capital
23
34
- -
20
1
1
LT Debt
-45
-36
-2
-19
-12
11
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
24
29
77
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
6
6
28
Cash, Cash Equivalents & STI
4
4
25
Accounts Receivable, Net
- -
- -
- -
Inventories
2
2
1
Total Current Liabilities
9
12
12
Payables & Accruals
9
11
11
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-37.55%
Free Cash Flow
- -
- -
-2.9%
Net Income, GAAP
- -
- -
14.24%
Sales/Revenue/Turnover
- -
- -
7.11%
Total Cash Common Dividend
- -
- -
0.42%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
TaiDoc Technology Corporation (4736.TW)
ViewRay, Inc. (VRAY)
EOFLOW Co.,Ltd. (294090.KQ)
Shanghai General Healthy Information and Technology Co., Ltd. (605186.SS)
STRATA Skin Sciences, Inc. (SSKN)
Carvolix S.A. (CVX.PA)
Business
Envoy Medical, Inc. (NASDAQ: COCH) develops and commercializes innovative hearing health technologies across the hearing loss spectrum, including fully implanted devices that leverage natural ear anatomy for improved access, usability and quality of life; its core products comprise the FDA-approved Esteem fully implanted active middle ear implant for moderate to severe sensorineural hearing loss, commercially available in the U.S. since 2010, personal sound amplification products, bone conduction devices such as auditory osseointegrated implants for conductive and mixed hearing losses, and the investigational Acclaim fully implanted cochlear implant for severe to profound sensorineural hearing loss. Founded in 1995 and headquartered in White Bear Lake, Minnesota, the company primarily serves patients and healthcare providers in the United States through its medical device offerings in the surgical and medical apparatus industry. In recent developments, Envoy Medical changed its name from Envoy Medical Corporation in September 2023, eliminated $32 million in debt during third-quarter 2025, received FDA approval in October 2025 to advance its Acclaim pivotal clinical trial to the final stage based on promising data from initial patients, enrolled the first three patients in that trial stage by early November 2025, completed a $2.5 million registered direct offering in September 2025 followed by up to $16 million in October 2025, secured multiple new U.S. patents including its 40th in December 2025 for cochlear implant innovations, achieved six-month milestones with the first 10 Acclaim trial patients in November 2025, and received a positive NASDAQ listing determination in October 2025.